The US Food and Drug Administration is asking its Oncologic Drugs Advisory Committee to take into consideration three factors in deciding whether future approvals in the phosphatidylinositol 3-kinase (PI3K) inhibitor class should be based upon randomized data.
There exists a narrow range between effective and toxic doses in this class and, to date, the sponsors of approved...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?